rupiya.io
⠋Loading...
0%
❯ Analyzing price movements...
Mankind Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Mankind Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | ₹3,334 Cr | ₹5,865 Cr | ₹6,214 Cr | ||||
| Expenses | ₹2,748 Cr | ₹4,427 Cr | ₹4,565 Cr | ||||
| Operating Profit | ₹586 Cr | ₹1,438 Cr | ₹1,649 Cr | ||||
| OPM % | 18.0% | 25.0% | 27.0% | ||||
| Other Income | ₹76 Cr | ₹122 Cr | ₹183 Cr | ||||
| Depreciation | ₹39 Cr | ₹99 Cr | ₹119 Cr | ||||
| Interest | ₹2 Cr | ₹23 Cr | ₹21 Cr | ||||
| Profit Before Tax | ₹621 Cr | ₹1,438 Cr | ₹1,692 Cr | ||||
| Tax | ₹621 Cr | ₹1,438 Cr | ₹1,692 Cr | ||||
| Net Profit | ₹445 Cr | ₹1,056 Cr | ₹1,293 Cr | ||||
| EPS (₹) | 219.3 | 25.7 | 31.6 | ||||
| Dividend Payout % | 0% | 0% | 24% |
Register free to see 4 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹2,091 Cr | ₹2,053 Cr | ₹2,579 Cr | ₹2,708 Cr | ||||||||
| Expenses | ₹1,654 Cr | ₹1,636 Cr | ₹1,924 Cr | ₹2,025 Cr | ||||||||
| Operating Profit | ₹437 Cr | ₹417 Cr | ₹655 Cr | ₹683 Cr | ||||||||
| OPM % | 21.0% | 20.0% | 25.0% | 25.0% | ||||||||
| Depreciation | ₹85 Cr | ₹85 Cr | ₹87 Cr | ₹96 Cr | ||||||||
| Interest | ₹13 Cr | ₹5 Cr | ₹6 Cr | ₹9 Cr | ||||||||
| Net Profit | ₹296 Cr | ₹294 Cr | ₹494 Cr | ₹511 Cr | ||||||||
| EPS (₹) | 7.1 | 7.1 | 12.2 | 12.5 |
Register free to see 8 more quarters.
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹20 Cr | ₹40 Cr | ₹40 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2,035 Cr | ₹3,445 Cr | ₹4,682 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹0 Cr | ₹131 Cr | ₹241 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹968 Cr | ₹1,449 Cr | ₹1,397 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹3,022 Cr | ₹5,065 Cr | ₹6,360 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹316 Cr | ₹1,600 Cr | ₹1,664 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹959 Cr | ₹829 Cr | ₹1,512 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹1,700 Cr | ₹2,319 Cr | ₹2,811 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹3,022 Cr | ₹5,065 Cr | ₹6,360 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 4 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2021 | ₹1,070 Cr | ₹-436 Cr | ₹-531 Cr | — |
| Mar 2022 | ₹1,137 Cr | ₹-1,222 Cr | ₹-8 Cr | — |
| Mar 2023 | ₹920 Cr | ₹-1,369 Cr | ₹605 Cr | — |
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 4 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.